Drug Approvals of 2006
Executive Summary
2006 proved to be a slightly better year for Big Pharma-and the industry at large-than 2005, at least when it came to approvals of innovative drugs.You may also be interested in...
The Approval Drought Continues
No matter how you look at the numbers, it was another bad year for new product launches in the US. FDA approved more new drugs than last year, but just barely. And the number of products going off-patent actually exceeded the number of new launches. The sparse crop of new drugs this decade means lean years ahead for the pharma industry.
DDD Bringing New Life To UK’s Baby-Care Category
DDD Ltd's global marketing director Katy Holder tells HBW Insight how the company is looking to carve out a niche in the UK's baby-care market with naturally derived ingredients and family-friendly product portfolios.
Upsher-Smith Launches Three New Generics
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports